值得注意的是，中国中药昨日股价暴跌35%，北水资金全天逢低吸筹，单日净买入额9.19亿港元。此外，根据联交所权益披露资料显示，2024年10月16日，中国中药获小摩增持1985.72万股，涉资约8606.13万港元。增持后，小摩最新持好仓数目为262,837,629股，持好仓比例由4.82%上升至5.21%。Trad chi med (00570) rebounded by over 5%, as of the time of publication, rose by 5.24% to 2.61 Hong Kong dollars, with a turnover of 0.402 billion Hong Kong dollars.
According to the Wisdom Finance APP, Trad chi med (00570) rebounded by over 5%, rising by 5.24% to 2.61 Hong Kong dollars as of the time of publication, with a turnover of 0.402 billion Hong Kong dollars.
On the news front, on October 18th, Trad chi med announced that due to the unsatisfactory fulfillment of prerequisites, its controlling shareholder, National Pharmaceutical Group, officially abandoned the privatization plan of Trad chi med at a price of 4.6 Hong Kong dollars per share. It is reported that in February of this year, Trad chi med announced that National Pharmaceutical Group planned to privatize Trad chi med at a price of 4.6 Hong Kong dollars per share. Regarding the reason for this privatization, Trad chi med believes that due to limited trading volume in the secondary market, its function as a financing platform for a listed company is restricted.
It is worth noting that the stock price of Trad chi med plummeted by 35% yesterday, with Beishui funds buying on dips throughout the day, with a net purchase amount of 0.919 billion Hong Kong dollars in a single day. In addition, according to the HKEX equity disclosure data, on October 16, 2024, Trad chi med received a shareholding increase of 19.8572 million shares from Morgan Stanley, involving approximately 86.0613 million Hong Kong dollars. After the increase in shareholding, Morgan Stanley's latest number of held long positions is 262,837,629 shares, and the held long position ratio has increased from 4.82% to 5.21%.
